Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 18;14(3):456-460.
doi: 10.18240/ijo.2021.03.20. eCollection 2021.

Intracameral anti-VEGF injection for advanced neovascular glaucoma after vitrectomy with silicone oil tamponade

Ling Bai  1 , Farheen Tariq  1 , Yi-Dan He  1 , Shu Zhang  2   3 , Feng Wang  1
Affiliations

Intracameral anti-VEGF injection for advanced neovascular glaucoma after vitrectomy with silicone oil tamponade

Ling Bai et al. Int J Ophthalmol. .

Abstract

Aim: To evaluate the effect of intracameral injection of conbercept for the treatment of advanced neovascular glaucoma (NVG) after vitrectomy with silicone oil tamponade.

Methods: Conbercept 0.5 mg/0.05 mL was injected into the anterior chamber of 5 eyes, which had developed advanced NVG after vitrectomy with silicone oil tamponade. Then, trabeculectomy with mitomycin C and pan-retinal photocoagulation (PRP) or extra-PRP were conducted within 2d. The follow-up time was 6mo. Best-corrected visual acuity (BCVA), intraocular pressure (IOP), neovascularization of iris (NVI) were recorded before and after treatment.

Results: Within 2d after injection, IOP control, and NVI regression were optimal for trabeculectomy. Hyphema occurred in one eye in the process of injection. But none of them present hyphema after trabeculectomy. At the end of follow-up time, all eyes had improved BCVA, well-controlled IOP, and completely regressed NVI.

Conclusion: Intracameral injection of conbercept is safe and effective in the treatment of patients with advanced NVG after vitrectomy with silicone oil tamponade. Within 2d after injection is the optimal time window for trabeculectomy, which can maximally reduce the risk of perioperative hyphema.

Keywords: anti-vascular endothelial growth factor therapy; conbercept; neovascular glaucoma; silicone oil; vitrectomy.

PubMed Disclaimer

Figures

Figure 1
Figure 1. The therapeutic regimen for advances NVG after vitrectomy with silicone oil tamponade.
Figure 2
Figure 2. Ophthalmic examination of the typical case
A: At the initial stage, edema occurred in the cornea, there was obvious NVI in the iris, IOP was 58 mm Hg; B: Hyphema was presented on the 1st day after conbercept anterior chamber injection, but the cornea was clear, NVI disappeared at the visible superior iris, and IOP was 21 mm Hg; C-E: One day after trabeculectomy with mitomycin C plus anterior chamber irrigation, hyphema was almost disappeared, there was only slight residual NVI, and the filtering bleb was diffused; F: Six months later, the cornea was clear, and no neovessels could be found on the iris or in the angle.
See this image and copyright information in PMC

References

    1. Simha A, Aziz K, Braganza A, Abraham L, Samuel P, Lindsley KB. Anti-vascular endothelial growth factor for neovascular Glaucoma. Cochrane Database Syst Rev. 2020;2:CD007920. - PMC - PubMed
    1. Zhou M, Chen S, Wang W, Huang W, Cheng B, Ding X, Zhang X. Levels of erythropoietin and vascular endothelial growth factor in surgery-required advanced neovascular glaucoma eyes before and after intravitreal injection of bevacizumab. Invest Ophthalmol Vis Sci. 2013;54(6):3874–3879. - PubMed
    1. Kuzmin A, Lipatov D, Chistyakov T, Smirnova O, Arbuzova M, Ilin A, Shestakova M, Dedov I. Vascular endothelial growth factor in anterior chamber liquid patients with diabetic retinopathy, cataract and neovascular glaucoma. Ophthalmol Ther. 2013;2(1):41–51. - PMC - PubMed
    1. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM. Intravitreal bevacizumab (avastin®) in the treatment of neovascular glaucoma. Am J Ophthalmol. 2006;142(6):1054–1056. - PubMed
    1. Andrés-Guerrero V, Perucho-González L, García-Feijoo J, Morales-Fernández L, Saenz-Francés F, Herrero-Vanrell R, Júlvez LP, Llorens VP, Martínez-De-la-casa JM, Konstas AG. Current perspectives on the use of anti-VEGF drugs as adjuvant therapy in glaucoma. Adv Ther. 2017;34(2):378–395. - PMC - PubMed

LinkOut - more resources